Given its involvement in cancer progression, fibronectin is being explored as a target for cancer therapy. Strategies to inhibit fibronectin include the use of antibodies that block its interaction with cell surface receptors or small molecules that disrupt its structure and function. These approaches aim to reduce tumor growth and metastasis by interfering with the supportive role of fibronectin in the tumor microenvironment.
